APL-030 / Apollo Therap - LARVOL DELTA

Preclinical assessment of APL-030, a selective and orally bioavailable inhibitor of the integrated stress response regulator GCN2 with activity against acute myeloid leukemia (AACR 2024) - "APL-030 is a novel GCN2 inhibitor that that has shown encouraging efficacy in preclinical studies using both AML cell lines and patient-derived AML samples. Based on these preclinical results, a phase 1/2 study is planned in hematological tumors."

IO biomarker • Preclinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • ANXA5 • ATF4 • CASP3 • CASP7 • CD34 • CHAC1 • DDIT3 • PTPRC

Apollo’s APL-030 shows potent antitumor activity in both in vitro and in vivo AML (Bioworld) - "In tumors with amino acid deprivation, eIF-2α kinase GCN2 is activated and triggers a signaling response to promote cell survival and proliferation. This is important in high metabolically active hematological cancers, such as acute myeloid leukemia (AML)."

Preclinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology